Lantern Pharma is trading at $2.64 (5.7% down) in after-hours trading on apparent profit-taking following a multi-day rally.
- The stock is pulling back from its August 5 close of $2.80, with the move appearing to be normal volatility rather than the result of fresh company-specific headlines.
- Recent strength was driven by the late-July EMA clearance for the LP-184 Phase 1b/2 trial and the August 3 launch of the Open-Medicine AI spin-out.
- Shares had seen significant upward momentum prior to this session's retracement.